Streetbeat News

Products Services

BLK

BlackRock Inc. (NYSE:BLK) CEO Larry Fink highlights a shift in fixed-income markets as investors move from traditional bonds to ETFs and alternative assets. This trend, driven by expectations of a U.S. rate cut and a significant equity rally, has led to record inflows into BlackRock's ETF products and increased interest in infrastructure investments. BlackRock's quarterly revenue rose 8% to $4.81 billion, with net income surpassing expectations at $1.5 billion.

Portfolio Pulse from Benzinga Neuro

July 16, 2024 | 11:54 am

CDT

Conduit Pharmaceuticals shares are trading higher after the company announced it received patent approval for its lead asset targeting autoimmune diseases.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:50 am

LASE

Laser Photonics has introduced the new MarkStar Handheld VIN Marking Laser, aimed at preventing theft and counterfeiting.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:48 am

ANRO

Alto Neuroscience has completed enrollment in its Phase 2b study of ALTO-100, a treatment for Major Depressive Disorder. This milestone is significant for the company's progress in developing new treatments for mental health conditions.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:46 am

BAC

DJT

JBHT

MS

MTCH

QQQ

SPY

UNH

Wall Street is set to extend gains amid hopes for interest rate cuts, with bond yields slipping. Small-cap stocks are rallying, reflecting market optimism. Key economic data and earnings reports are expected to influence market movements. SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) showed premarket gains.

Portfolio Pulse from Shanthi Rexaline

July 16, 2024 | 11:46 am

CDT

Conduit Pharmaceuticals has announced the approval of a patent for its lead asset targeting autoimmune diseases. This development is expected to enhance the company's intellectual property portfolio and potentially accelerate its market presence in the autoimmune disease treatment sector.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:44 am

ANRO

Alto Neuroscience has completed enrollment for its ALTO-100 Phase 2b study, with 300 patients participating. The company is on track to report topline results in October 2024 and will host an investor day on September 9, 2024, focused on ALTO-100.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:36 am

RDW

Redwire has secured a follow-on order for its Roll-Out Solar Arrays (ROSA) from Thales Alenia Space for their newest telecommunications satellite product line.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:36 am

MDWD

MediWound has been selected to receive €16.25 million in funding from the European Innovation Council Accelerator Program. This funding will support the development and commercialization of its innovative therapies.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:34 am

BTAI

BioXcel Therapeutics announced preliminary Q2 sales of Igalmi (Dexmedetomidine) sublingual film at approximately $1.1M, marking a 90% increase quarter-over-quarter and a 141% increase year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 11:31 am